BioNTech stock fell 1.96 percent despite a Buy consensus

BioNTech SE stock (ISIN US09075V1026) was last at USD 95.73 on Nasdaq on October 6, 2026, down 1.96 percent from the previous close. The company is valued at USD 24.0 billion, while analysts still see a higher average target.

Analysts see room above USD 95.73

According to Stock Analysis on October 6, 2026, the consensus rating was Buy across 20 analysts, with an average price target of USD 115.67. That target lies 20.83 percent above the USD 95.73 reference price.

The consensus is not uniform across the market. MarketBeat reported a Moderate Buy view from 19 brokerages, with 12 Buy ratings, five Holds, one Sell and one Strong Buy, plus an average target of USD 126.00. The spread between the two published averages shows how much the valuation depends on the analyst sample and its treatment of BioNTech's pipeline.

Second-quarter losses remain the counterweight

BioNTech's latest reported quarter was Q2 2026. MarketBeat said revenue fell 59.5 percent year over year to USD 122.31 million, while the company posted an adjusted EPS loss of USD 2.53 against a USD 2.40 consensus loss. The revenue shortfall was USD 57.87 million versus the published USD 180.18 million estimate.

The operating reset adds a second factor for investors. Reuters reported on September 28, 2026, that BioNTech would close sites in Marburg, Idar-Oberstein and Tübingen after a sale process did not produce a buyer. The restructuring affects up to 1,860 positions as production shifts toward Pfizer and the company concentrates more heavily on oncology.

Nasdaq valuation and next date

BioNTech's October 6, 2026 market capitalization was USD 24.0 billion, with 882,704 shares traded. The 52-week range was USD 79.52 to USD 124.00, placing the latest price USD 28.27 below the high and USD 16.21 above the low.

For investors, the central contrast is quantitative: the current price is below the published consensus targets, but the most recent quarter combined a USD 122.31 million revenue base with a USD 2.53 adjusted EPS loss. Stock Analysis lists November 3, 2026, before market open, as the next confirmed earnings date.

BioNTech stock stays below USD 100

BioNTech stock was last at USD 95.73 on Nasdaq on October 6, 2026, at 4:00 p.m. ET. The next earnings date is November 3, 2026.

Upcoming dates for BioNTech stock

• November 3, 2026: Second-quarter earnings report before market open

More news and analyses on BioNTech stock